Deciphera Pharmaceuticals, LLC
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Methods of Treating Disorders Using CSF1R Inhibitors (US 11,679,110) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities (US 9,133,183) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 4 fees due Apr 10 to 30, 2027 · next Apr 10
- 3 fees due May 10 to 24, 2027 · next May 10
- 2 fees due Jun 19 to 26, 2027 · next Jun 19
- 4 fees due Aug 13 to 27, 2027 · next Aug 13
- 1 fee due Sep 5, 2027The maintenance fee for Compositions of 1-(4-Bromo-5-(1-Ethyl-7-(METHYLAMINO)-2-OXO-1,2-Dihydro-1,6-Naphthyridin-3-YL)-2-Fluoropheyl)-3-Phenylurea (US 11,918,564) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 3 fees due Oct 12 to 30, 2027 · next Oct 12
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,790,756 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,586,565 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,163,756 | Enzyme modulators and treatments In force · From the USPTO record | In force | From the USPTO record | |
| US 8,188,113 | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases In force (reinstated) · From the USPTO record | In force (reinstated) | From the USPTO record | |
| US RE48,731 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,133,183 | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities In force · From the USPTO record | In force | From the USPTO record | |
| US 9,181,223 | 2-Aminopyrimidin-6-ONES and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities In force · High confidence | In force | High confidence | |
| US 9,193,719 | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities In force · From the USPTO record | In force | From the USPTO record | |
| US 9,309,224 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities In force · From the USPTO record | In force | From the USPTO record | |
| US 9,382,228 | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 77: 2 patents in force now held by others · 19 lapsed for an unpaid fee · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 7 abandoned · 22 no status recorded